CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Balance Sheet
NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 2.98M | 3.38M | 18.35M | 36.56M | 33.41M | |||
| Receivables | 1.25M | 2.93M | 4.66M | 3.73M | 1.31M | |||
| Other Current Assets | 683.00K | 1.13M | 1.41M | 660.00K | 750.00K | |||
| Total Current Assets | 4.91M | 7.44M | 24.41M | 40.94M | 35.47M | |||
| Non-Current Assets | ||||||||
| PPE Net | 55.00K | 102.00K | 170.00K | 90.00K | 1.33M | |||
| Other Non-Current Assets | 413.00K | 1.26M | 2.92M | 1.55M | N/A | |||
| Total Non-Current Assets | 468.00K | 1.36M | 3.09M | 1.65M | 1.33M | |||
| TOTAL ASSETS | 5.38M | 8.80M | 27.50M | 42.59M | 36.80M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 1.89M | 4.24M | 3.94M | 2.54M | 1.11M | |||
| Accounts Payable | 4.13M | 3.54M | 2.56M | 2.12M | 510.00K | |||
| Other Current Liabilities | 332.00K | 380.00K | 890.00K | 630.00K | 870.00K | |||
| Total Current Liabilities | 6.35M | 8.16M | 7.39M | 5.29M | 2.49M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 0.00 | 37.00K | 110.00K | 30.00K | 1.06M | |||
| Total Non-Current Liabilities | 0.00 | 37.00K | 110.00K | 30.00K | 1.05M | |||
| TOTAL LIABILITIES | 6.35M | 8.20M | 7.50M | 5.32M | 3.54M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -436.44M | -428.28M | -406.16M | -384.96M | -366.07M | |||
| Additional Paid In Capital | 436.50M | 429.80M | 422.97M | 422.96M | 400.07M | |||
| Common Shares | 2.00K | 1.00K | 4.50M | 10.00K | 10.00K | |||
| Other Shareholders' Equity | -1.03M | -908.00K | -1.32M | -750.00K | -750.00K | |||
| Shares Outstanding | 2.15M | 1.06M | 12.54M | 9.99M | 6.25M | |||
| Tangible Book Value per Share | -0.45 | 0.57 | 1.59 | 3.73 | 5.32 | |||
| Total Shareholders' Equity | -970.00K | 607.00K | 20.00M | 37.26M | 33.26M | |||
| TOTAL LIABILITIES AND EQUITY | 5.38M | 8.80M | 27.50M | 42.59M | 36.80M | |||
| Statistics | ||||||||
| Current Ratio | 0.77 | 0.91 | 3.30 | 7.74 | 14.24 | |||
| Return On Assets (ROA) | -250.53% | -258.44% | -77.82% | -44.82% | -33.75% | |||
| Return On Equity (ROE) | N/A | -3748.93% | -107.00% | -51.23% | -37.34% | |||
All data in USD , ROIC based on taxRate of 0.21